Trial Profile
Afatinib Plus Bevacizumab After Acquired Resistance to EGFR-TKI in EGFR-mutant NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2018
Price :
$35
*
At a glance
- Drugs Afatinib (Primary) ; Bevacizumab
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ABC-study
- 07 Sep 2018 Results published in the Cancer
- 24 Dec 2017 Status changed from recruiting to completed.
- 02 Jun 2017 Results (n=33) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.